Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1984 1
1985 3
1986 7
1987 9
1988 6
1989 9
1990 5
1991 10
1992 12
1993 14
1994 5
1995 8
1996 12
1997 8
1998 3
1999 4
2000 4
2001 4
2002 2
2003 3
2004 5
2005 6
2006 3
2007 6
2008 4
2009 4
2010 5
2011 9
2012 7
2013 9
2014 11
2015 10
2016 12
2017 10
2018 7
2019 8
2020 16
2021 14
2022 16
2023 11
2024 5

Text availability

Article attribute

Article type

Publication date

Search Results

281 results

Results by year

Filters applied: . Clear all
Page 1
Experts' consensus on the definition and management of high risk multiple myeloma.
Marcon C, Simeon V, Deias P, Facchin G, Corso A, Derudas D, Montefusco V, Offidani M, Petrucci MT, Zambello R, Stocchi R, Fanin R, Patriarca F. Marcon C, et al. Among authors: zambello r. Front Oncol. 2023 Jan 23;12:1096852. doi: 10.3389/fonc.2022.1096852. eCollection 2022. Front Oncol. 2023. PMID: 36755858 Free PMC article. Review.
Carfilzomib with cyclophosphamide and dexamethasone or lenalidomide and dexamethasone plus autologous transplantation or carfilzomib plus lenalidomide and dexamethasone, followed by maintenance with carfilzomib plus lenalidomide or lenalidomide alone for patients with newly diagnosed multiple myeloma (FORTE): a randomised, open-label, phase 2 trial.
Gay F, Musto P, Rota-Scalabrini D, Bertamini L, Belotti A, Galli M, Offidani M, Zamagni E, Ledda A, Grasso M, Ballanti S, Spadano A, Cea M, Patriarca F, D'Agostino M, Capra A, Giuliani N, de Fabritiis P, Aquino S, Palmas A, Gamberi B, Zambello R, Petrucci MT, Corradini P, Cavo M, Boccadoro M. Gay F, et al. Among authors: zambello r. Lancet Oncol. 2021 Dec;22(12):1705-1720. doi: 10.1016/S1470-2045(21)00535-0. Epub 2021 Nov 11. Lancet Oncol. 2021. PMID: 34774221 Free article. Clinical Trial.
Not all LGL leukemias are created equal.
Semenzato G, Calabretto G, Barilà G, Gasparini VR, Teramo A, Zambello R. Semenzato G, et al. Among authors: zambello r. Blood Rev. 2023 Jul;60:101058. doi: 10.1016/j.blre.2023.101058. Epub 2023 Feb 20. Blood Rev. 2023. PMID: 36870881 Free article. Review.
All that glitters is not LGL Leukemia.
Semenzato G, Teramo A, Calabretto G, Gasparini VR, Zambello R. Semenzato G, et al. Among authors: zambello r. Leukemia. 2022 Nov;36(11):2551-2557. doi: 10.1038/s41375-022-01695-x. Epub 2022 Sep 15. Leukemia. 2022. PMID: 36109593 Review.
MATRix-RICE therapy and autologous haematopoietic stem-cell transplantation in diffuse large B-cell lymphoma with secondary CNS involvement (MARIETTA): an international, single-arm, phase 2 trial.
Ferreri AJM, Doorduijn JK, Re A, Cabras MG, Smith J, Ilariucci F, Luppi M, Calimeri T, Cattaneo C, Khwaja J, Botto B, Cellini C, Nassi L, Linton K, McKay P, Olivieri J, Patti C, Re F, Fanni A, Singh V, Bromberg JEC, Cozens K, Gastaldi E, Bernardi M, Cascavilla N, Davies A, Fox CP, Frezzato M, Osborne W, Liberati AM, Novak U, Zambello R, Zucca E, Cwynarski K; International Extranodal Lymphoma Study Group (IELSG). Ferreri AJM, et al. Among authors: zambello r. Lancet Haematol. 2021 Feb;8(2):e110-e121. doi: 10.1016/S2352-3026(20)30366-5. Lancet Haematol. 2021. PMID: 33513372 Free PMC article. Clinical Trial.
Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study.
Cavo M, Gay F, Beksac M, Pantani L, Petrucci MT, Dimopoulos MA, Dozza L, van der Holt B, Zweegman S, Oliva S, van der Velden VHJ, Zamagni E, Palumbo GA, Patriarca F, Montefusco V, Galli M, Maisnar V, Gamberi B, Hansson M, Belotti A, Pour L, Ypma P, Grasso M, Croockewit A, Ballanti S, Offidani M, Vincelli ID, Zambello R, Liberati AM, Andersen NF, Broijl A, Troia R, Pascarella A, Benevolo G, Levin MD, Bos G, Ludwig H, Aquino S, Morelli AM, Wu KL, Boersma R, Hajek R, Durian M, von dem Borne PA, Caravita di Toritto T, Zander T, Driessen C, Specchia G, Waage A, Gimsing P, Mellqvist UH, van Marwijk Kooy M, Minnema M, Mandigers C, Cafro AM, Palmas A, Carvalho S, Spencer A, Boccadoro M, Sonneveld P. Cavo M, et al. Among authors: zambello r. Lancet Haematol. 2020 Jun;7(6):e456-e468. doi: 10.1016/S2352-3026(20)30099-5. Epub 2020 Apr 30. Lancet Haematol. 2020. PMID: 32359506 Clinical Trial.
Long-term follow-up of rituximab plus bendamustine and cytarabine in older patients with newly diagnosed MCL.
Tisi MC, Moia R, Patti C, Evangelista A, Ferrero S, Spina M, Tani M, Botto B, Celli M, Puccini B, Cencini E, Di Rocco A, Chini C, Ghiggi C, Zambello R, Zanni M, Sciarra R, Bruna R, Ferrante M, Pileri SA, Quaglia FM, Stelitano C, Re A, Volpetti S, Zilioli VR, Arcari A, Merli F, Visco C. Tisi MC, et al. Among authors: zambello r. Blood Adv. 2023 Aug 8;7(15):3916-3924. doi: 10.1182/bloodadvances.2023009744. Blood Adv. 2023. PMID: 37171620 Free PMC article.
Rituximab-responsive CIDP.
Briani C, Zara G, Zambello R, Trentin L, Rana M, Zaja F. Briani C, et al. Among authors: zambello r. Eur J Neurol. 2004 Nov;11(11):788. doi: 10.1111/j.1468-1331.2004.00911.x. Eur J Neurol. 2004. PMID: 15525302 No abstract available.
281 results